Trial · NCT04876391
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Prior Placebo (PP) | 15 | Participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Prior Spesolimab (PS) | 28 | Participants | ||
| Percent Change in Total Abscess and Inflammatory Nodule (AN) Count From Baseline up to Week 12 | Prior Placebo (PP) | -18.3 | Standard Error 19.2 | Percentage change | |
| Percent Change in Total Abscess and Inflammatory Nodule (AN) Count From Baseline up to Week 12 | Prior Spesolimab (PS) | -35.0 | Standard Error 12.7 | Percentage change | |
| Percentage Change in Total Draining Fistula (DF) Count From Baseline up to Week 12 | Prior Placebo (PP) | 25.4 | Standard Error 25.5 | Percentage change | |
| Percentage Change in Total Draining Fistula (DF) Count From Baseline up to Week 12 | Prior Spesolimab (PS) | -44.6 | Standard Error 18.1 | Percentage change | |
| Achievement of Hidradenitis Suppurativa Clinical Response (HiSCR) up to Week 12 | Prior Placebo (PP) | 33.3 | 95% Confidence Interval 13.8 to 60.9 | Percentage of participants | |
| Achievement of Hidradenitis Suppurativa Clinical Response (HiSCR) up to Week 12 | Prior Spesolimab (PS) | 40.7 | 95% Confidence Interval 24.5 to 59.3 | Percentage of participants | |
| Change From Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) Value up to Week 12 | Prior Placebo (PP) | -3.1 | Standard Error 4.8 | Score on a scale | |
| Change From Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) Value up to Week 12 | Prior Spesolimab (PS) | -10.5 | Standard Error 3.3 | Score on a scale | |
| Percentage of Participants With Hidradenitis Suppurativa Physician Global Assessment (HS-PGA) Score of 0 or 1 up to Week 12 | Prior Placebo (PP) | 0 | 95% Confidence Interval 0 to 22.8 | Percentage of participants | |
| Percentage of Participants With Hidradenitis Suppurativa Physician Global Assessment (HS-PGA) Score of 0 or 1 up to Week 12 | Prior Spesolimab (PS) | 3.7 | 95% Confidence Interval 0.7 to 18.3 | Percentage of participants | |
| Absolute Change From Baseline in Hidradenitis Suppurativa Area and Severity Index (HASI) Score up to Week 12 | Prior Placebo (PP) | 5.0 | Standard Error 8.9 | Score on a scale | |
| Absolute Change From Baseline in Hidradenitis Suppurativa Area and Severity Index (HASI) Score up to Week 12 | Prior Spesolimab (PS) | -22.8 | Standard Error 6.1 | Score on a scale | |
| Patients With Occurrence of at Least One Flare (Defined as at Least 25 % Increase in AN Count With a Minimum Increase of 2 Relative to Baseline) up to Week 12 | Prior Placebo (PP) | 8.3 | 95% Confidence Interval 1.5 to 35.4 | Percentage of participants | |
| Patients With Occurrence of at Least One Flare (Defined as at Least 25 % Increase in AN Count With a Minimum Increase of 2 Relative to Baseline) up to Week 12 | Prior Spesolimab (PS) | 14.8 | 95% Confidence Interval 5.9 to 32.5 | Percentage of participants | |
| Achievement of at Least 30% Reduction From Baseline in Numerical Rating Scale (NRS30) in Patient's Global Assessment of HS Pain up to Week 12 | Prior Placebo (PP) | 25.0 | 95% Confidence Interval 8.9 to 53.2 | Percentage of participants | |
| Achievement of at Least 30% Reduction From Baseline in Numerical Rating Scale (NRS30) in Patient's Global Assessment of HS Pain up to Week 12 | Prior Spesolimab (PS) | 33.3 | 95% Confidence Interval 20.2 to 55.5 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04876391/results